CY1113930T1 - Ενωσεις χρησιμες στην αναστολη της chk1 - Google Patents
Ενωσεις χρησιμες στην αναστολη της chk1Info
- Publication number
- CY1113930T1 CY1113930T1 CY20131100305T CY131100305T CY1113930T1 CY 1113930 T1 CY1113930 T1 CY 1113930T1 CY 20131100305 T CY20131100305 T CY 20131100305T CY 131100305 T CY131100305 T CY 131100305T CY 1113930 T1 CY1113930 T1 CY 1113930T1
- Authority
- CY
- Cyprus
- Prior art keywords
- useful
- chk1
- unions
- suspension
- solvate
- Prior art date
Links
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 title 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- -1 aminopyrazole compound Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 101150113535 chek1 gene Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13817608P | 2008-12-17 | 2008-12-17 | |
| EP09768586A EP2379532B1 (en) | 2008-12-17 | 2009-12-10 | Compounds useful for inhibiting chk1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113930T1 true CY1113930T1 (el) | 2016-07-27 |
Family
ID=42079067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100305T CY1113930T1 (el) | 2008-12-17 | 2013-04-11 | Ενωσεις χρησιμες στην αναστολη της chk1 |
Country Status (37)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314108B2 (en) * | 2008-12-17 | 2012-11-20 | Eli Lilly And Company | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts |
| JO3145B1 (ar) * | 2010-11-08 | 2017-09-20 | Lilly Co Eli | مركبات مفيدة لتثبيط chk1 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| TWI725041B (zh) * | 2015-07-23 | 2021-04-21 | 美商美國禮來大藥廠 | 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑 |
| TWI627168B (zh) * | 2015-12-07 | 2018-06-21 | 美國禮來大藥廠 | (s)-乳酸鹽 |
| SG11201803903YA (en) * | 2015-12-15 | 2018-06-28 | Lilly Co Eli | Combination therapy for cancer |
| WO2017132928A1 (en) * | 2016-02-04 | 2017-08-10 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| AU2018243667A1 (en) | 2017-03-31 | 2019-10-17 | Seagen Inc. | Combinations of Chk1- and Wee1 - inhibitors |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| CN112457306A (zh) | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| US11634424B2 (en) | 2019-11-29 | 2023-04-25 | Medshine Discovery Inc. | Diazaindole derivative and use thereof as CHK1 inhibitor |
| WO2021119236A1 (en) | 2019-12-10 | 2021-06-17 | Seagen Inc. | Preparation of a chk1 inhibitor compound |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| AU2021389190A1 (en) | 2020-11-30 | 2023-06-29 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1h-pyrazol-3-amine derivative |
| KR20240021188A (ko) * | 2021-05-27 | 2024-02-16 | 바운드리스 바이오, 인크. | 체크포인트 키나제 1(chk1) 억제제 및 그의 용도 |
| GB202107932D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | Preparation of a CHK1 Inhibitor Compound |
| GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
| MX2024007910A (es) | 2021-12-24 | 2024-09-04 | Sumitomo Pharma Co Ltd | Derivado de 1h-pirazol-3-amina que tiene una estructura principal bicíclica. |
| EP4534100A1 (en) * | 2022-05-27 | 2025-04-09 | Sumitomo Pharma Co., Ltd. | Therapeutic for cancer refractory to immune checkpoint inhibitor |
| JP7546104B2 (ja) * | 2022-05-27 | 2024-09-05 | 住友ファーマ株式会社 | ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体からなる医薬 |
| GB202213792D0 (en) | 2022-09-21 | 2022-11-02 | Benevolentai Bio Ltd | New compounds and method |
| GB202403910D0 (en) | 2024-03-19 | 2024-05-01 | Benovental Cambridge Ltd | New processes and intermediates for pharmaceutical products |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
| BRPI0412820A (pt) * | 2003-07-25 | 2006-09-26 | Pfizer | compostos de aminopirazol e utilização como inibidores de chk1 |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| US20090270418A1 (en) * | 2008-01-09 | 2009-10-29 | Marianne Sloss | Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith |
-
2009
- 2009-11-26 PA PA20098850801A patent/PA8850801A1/es unknown
- 2009-12-01 JO JO2009456A patent/JO2886B1/en active
- 2009-12-03 TW TW098141394A patent/TWI436996B/zh active
- 2009-12-03 AR ARP090104673A patent/AR074471A1/es not_active Application Discontinuation
- 2009-12-10 CA CA2746423A patent/CA2746423C/en not_active Expired - Fee Related
- 2009-12-10 JP JP2011542264A patent/JP5705743B2/ja active Active
- 2009-12-10 EP EP09768586A patent/EP2379532B1/en active Active
- 2009-12-10 BR BRPI0922468-8A patent/BRPI0922468A2/pt active Search and Examination
- 2009-12-10 ES ES09768586T patent/ES2401558T3/es active Active
- 2009-12-10 UA UAA201107564A patent/UA101998C2/ru unknown
- 2009-12-10 SI SI200930559T patent/SI2379532T1/sl unknown
- 2009-12-10 DK DK09768586.1T patent/DK2379532T3/da active
- 2009-12-10 HR HRP20130167AT patent/HRP20130167T1/hr unknown
- 2009-12-10 MX MX2011006603A patent/MX2011006603A/es active IP Right Grant
- 2009-12-10 EA EA201170834A patent/EA018118B1/ru not_active IP Right Cessation
- 2009-12-10 NZ NZ593440A patent/NZ593440A/xx not_active IP Right Cessation
- 2009-12-10 SG SG2011044401A patent/SG172222A1/en unknown
- 2009-12-10 RS RS20130153A patent/RS52739B/sr unknown
- 2009-12-10 WO PCT/US2009/067437 patent/WO2010077758A1/en not_active Ceased
- 2009-12-10 AU AU2009333433A patent/AU2009333433B2/en not_active Ceased
- 2009-12-10 MY MYPI2011002767A patent/MY156998A/en unknown
- 2009-12-10 KR KR1020117013801A patent/KR101301777B1/ko not_active Expired - Fee Related
- 2009-12-10 PL PL09768586T patent/PL2379532T3/pl unknown
- 2009-12-10 PT PT97685861T patent/PT2379532E/pt unknown
- 2009-12-10 PE PE2011001140A patent/PE20120077A1/es active IP Right Grant
- 2009-12-10 CN CN200980150018.7A patent/CN102245597B/zh active Active
-
2011
- 2011-05-26 IL IL213160A patent/IL213160A/en not_active IP Right Cessation
- 2011-05-27 ZA ZA2011/03946A patent/ZA201103946B/en unknown
- 2011-06-01 HN HN2011001446A patent/HN2011001446A/es unknown
- 2011-06-10 TN TN2011000298A patent/TN2011000298A1/fr unknown
- 2011-06-13 DO DO2011000185A patent/DOP2011000185A/es unknown
- 2011-06-14 MA MA33944A patent/MA32901B1/fr unknown
- 2011-06-15 CO CO11074829A patent/CO6382122A2/es active IP Right Grant
- 2011-06-16 EC EC2011011136A patent/ECSP11011136A/es unknown
- 2011-06-16 CL CL2011001463A patent/CL2011001463A1/es unknown
- 2011-06-17 CR CR20110339A patent/CR20110339A/es unknown
-
2013
- 2013-04-11 CY CY20131100305T patent/CY1113930T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113930T1 (el) | Ενωσεις χρησιμες στην αναστολη της chk1 | |
| CY1124144T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
| CY1119199T1 (el) | Αναστολεις cdc7 | |
| TR200906131T1 (tr) | Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e | |
| CY1121334T1 (el) | Αναστολεας κινασης aurora a | |
| EA200970935A1 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
| UA118645C2 (uk) | Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| CY1120135T1 (el) | Αναστολεις κινασης τυροσινης bruton | |
| CY1124331T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
| EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
| CY1120741T1 (el) | Θεραπεια οζωδους σκληρυνσης | |
| CY1116628T1 (el) | Ενωσεις σπειρο-οξινδολιου και χρηση αυτων ως θεραπευτικοι παραγοντες | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
| EA201170832A1 (ru) | Пуриновые соединения | |
| EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
| EA201000895A1 (ru) | Композиции и способы для лечения лизосомных болезней | |
| CY1119432T1 (el) | Αναστολεiς πυραζολυλ-γουανιδινο-f1f0-ατρασης και θεραπευτικες χρησεις αυτωn | |
| EA201390499A1 (ru) | Соединения, подходящие для ингибирования снк1 | |
| ATE458487T1 (de) | Tumorbehandlung mit gliotoxin-derivaten | |
| EA200971067A1 (ru) | Триазолиламинопиримидиновые соединения | |
| CY1116362T1 (el) | Ενωσεις χρησιμες στην αναστολη της chk1 | |
| CY1114609T1 (el) | Μεθοδοι θεραπειας καρκινου χρησιμοποιωντας αναστολεις p13k αλφα με βαση πυριδοπυριμιδινονη | |
| CY1115576T1 (el) | Αναστολεις jακ2 και χρηση αυτων για τη θεραπεια μυελοπολλαπλασιαστικων ασθενειων και καρκινου |